New Guidance in Lowering LDL-C

A panel of cardiologists discuss the key updates from the 2022 ACC Expert Consensus Decision Pathway on the role of nonstatin therapies for LDL-C lowering in the management of atherosclerotic cardiovascular disease risk.

Related Keywords

Bogalusa ,Louisiana ,United States ,Payal Kohli ,Christiem Ballantyne ,Keithc Ferdinand ,Erind Michos , ,Cardiology Expert Consensus Decision Pathway ,Bogalusa Heart Study ,Consensus Decision Pathway ,South Asian ,Ldl C ,Cardiovascular Disease ,Cardiovascular Risk ,Hyperlipidemia ,Primary Prevention ,Secondary Prevention ,Ascvd ,Statins ,High Risk ,Lifetime Risk Of Ascvd ,